Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 6, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Sep 30, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Sep 15, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record2,50616 flagged findings
Reported transactions (Form 4)80since May 12, 2023 · and 4 other holdings
Corporate events (8-K)30since Feb 14, 2022
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-05share offering or dilution eventrecentOpen filing ↗“…Significant Accounting Policies to the Company’s Consolidated Financial Statements included in the Company’s Annual Report on Form…”
+1 more passage from the same document
- “…Our $1.5 billion (undiscounted) of long-term debt as of March 31, 2026 will impact our liquidity due to the semi-annual cash…”
- 2026-05-05capital return (buybacks/dividends)recentOpen filing ↗“…market prices of our common stock. In addition, the existence of the 2027 Notes may encourage short selling by market participants…”
+1 more passage from the same document
- “…the 2027 Notes may encourage short selling by market participants because the conversion of the 2027 Notes could be used to satisfy…”
- 2026-05-05regulatory investigationrecentOpen filing ↗“…Liabilities are evaluated and refined each reporting period as additional information is known. Any receivables for insurance…”
+1 more passage from the same document
- “…we seek to comply with these safe harbors. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which…”
- 2026-05-05Department of Justice inquiryrecentOpen filing ↗“…Europe for allegedly violating the GDPR’s cross-border data transfer limitations. Additionally, companies that transfer…”
+1 more passage from the same document
- “…refined each reporting period as additional information is known. Any receivables for insurance recoveries for these liability claims…”
- 2026-05-05merger or acquisition eventrecentOpen filing ↗“…the three months ended March 31, 2026, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act)…”
+1 more passage from the same document
- “…Item 6. Exhibits Exhibit Number Description 2.1 Agreement and Plan of Merger, dated as of May 16, 2025, by and among Inozyme…”
- 2026-04-27merger or acquisition eventrecentOpen filing ↗“…with Amicus Therapeutics, Inc., a Delaware corporation (“ Amicus ”), pursuant to that certain Agreement and Plan of Merger (the “…”
+1 more passage from the same document
- “…provided pursuant to Section 13(a) of the Exchange Act. ☐ Introductory Note On April 27, 2026 (the “ Closing Date ”), BioMarin…”
- 2026-04-23merger or acquisition eventrecentOpen filing ↗“…period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the…”
+1 more passage from the same document
- “…new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01 Other Events. As…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 2,506)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 6, 268-K ↗Current report · Results
- Oct 1, 26Form 4 ↗Insider transaction
- Sep 30, 268-K ↗Current report · Entered a material agreement
- Sep 15, 268-K ↗Current report · Other events
- Sep 14, 26Form 4 ↗Insider transaction
- Sep 14, 26Form 3 ↗Insider transaction
- Sep 14, 268-K ↗Current report · A senior executive left or was appointed
- Sep 3, 26Form 4 ↗Insider transaction
- Sep 2, 26Form 144 ↗Notice of proposed sale
- Sep 1, 268-K ↗Current report · Other events
- Aug 31, 268-K ↗Current report · Entered a material agreement
- Aug 18, 268-K ↗Current report · Entered a material agreement
- Aug 6, 2610-Q ↗Quarterly report
- Aug 6, 268-K ↗Current report · Results
- Jul 13, 268-K/A ↗Current report · Other events · amendment
Insider transaction · 9 Form 4 filingsshow all 9hide
- Jun 4, 26Form 4 ↗Insider transaction
- Jun 4, 26Form 4 ↗Insider transaction
- Jun 4, 26Form 4 ↗Insider transaction
- Jun 4, 26Form 4 ↗Insider transaction
- Jun 4, 26Form 4 ↗Insider transaction
- Jun 4, 26Form 4 ↗Insider transaction
- Jun 4, 26Form 4 ↗Insider transaction
- Jun 4, 26Form 4 ↗Insider transaction
- Jun 4, 26Form 4 ↗Insider transaction
- Jun 4, 268-K ↗Current report · A senior executive left or was appointed
2,506 filings on record, the oldest from Jul 29, 99.
Listing the 25 most recent filings of the 2,506 on record.
310861
- Sep 30, 26Entered a material agreement8-K 1.01 ↗
- Sep 14, 26A senior executive left or was appointed8-K 5.02 ↗
- Aug 31, 26Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Aug 18, 26Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Jun 4, 26A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Apr 27, 26Entered a material agreement+4 more in the same filing8-K 1.01 ↗
- Feb 12, 26Took on a new financial obligation+3 more in the same filing8-K 2.03 ↗
- Dec 19, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
4 senior executive changes2025show all 4hide
- Dec 17, 25A senior executive left or was appointed8-K 5.02 ↗
- Aug 11, 25A senior executive left or was appointed8-K 5.02 ↗
- Aug 1, 25A senior executive left or was appointed8-K 5.02 ↗
- May 22, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- May 16, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Feb 24, 25A senior executive left or was appointed8-K 5.02 ↗
- Sep 4, 24Entered a material agreement+2 more in the same filing8-K 1.01 ↗
10 older filings not shown · The record reaches back to Oct 18, 04.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Aug 28, 24Restructuring plan with committed costs8-K 2.05 ↗
- May 14, 24Restructuring plan with committed costs8-K 2.05 ↗
- Oct 7, 22Restructuring plan with committed costs8-K 2.05 ↗
The full record holds 3 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- BlackRock, Inc.9.1%Dec 31, 25SCHEDULE 13G/A ↗1 earlier filing
- PRIMECAP MANAGEMENT CO/CA/8.2%Jun 30, 25SCHEDULE 13G/A ↗
- Vanguard Capital Management5.3%Mar 31, 26SCHEDULE 13G ↗
- Capital Research Global Investors4.8%Mar 31, 25SCHEDULE 13G/A ↗1 earlier filing
- VIKING GLOBAL INVESTORS LP4.3%Sep 30, 25SCHEDULE 13G/A ↗13 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Sep 2, Davis George Eric filed notice of intent to sell up to $1.2M.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $1.2M on Sep 2, per their Form 4. That is 100% of the shares announced so far, and the window is still open.
- Sep 2, 26Sell$1.2MGeorge Eric DavisEVP, Chief Legal Officer↗
- May 7, 26Sell$177KGregory R FribergEVP, Chief R&D Officer↗
- Mar 11, 26Sell$997KCharles Greg GuyerEVP, Chief Technical Officer↗
- Feb 26, 26Sell$1.6MGeorge Eric DavisEVP, Chief Legal Officer↗
- Feb 26, 26Sell$382KGregory R FribergEVP, Chief R&D Officer↗
Stock compensation, tax and giftsshow the 35 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Sep 30, 26Tax$245KGregory R FribergEVP, Chief R&D Officer↗
- Sep 10, 26Compensationamount n/aRobert M Plenge↗
- Jun 2, 26Compensationamount n/aELIZABETH M ANDERSON↗
- Jun 2, 26Compensationamount n/aBarbara W. Bodem↗
- Jun 2, 26Compensationamount n/aIAN T CLARK↗
- Jun 2, 26Compensationamount n/aWillard H Dere↗
- Jun 2, 26Compensationamount n/aMark J Enyedy↗
- Jun 2, 26Compensationamount n/aROBERT J. HOMBACH↗
- Jun 2, 26Compensationamount n/aMaykin Ho↗
- Jun 2, 26Compensationamount n/aTimothy P Walbert↗
- Jun 2, 26Compensationamount n/aAthena Countouriotis↗
- May 20, 26Tax$116KCristin HubbardEVP, Chief Commercial Officer↗
- Mar 18, 26Tax$71KGeorge Eric DavisEVP, Chief Legal Officer↗
- Mar 17, 26Tax$91KGregory R FribergEVP, Chief R&D Officer↗
- Mar 17, 26Tax$70KCristin HubbardEVP, Chief Commercial Officer↗
- Mar 17, 26Tax$238KAlexander HardyChief Executive Officer↗
- Mar 17, 26Tax$119KBrian MuellerEVP, Chief Financial Officer↗
- Mar 17, 26Tax$95KCharles Greg GuyerEVP, Chief Technical Officer↗
- Mar 16, 26Compensationamount n/aAlexander HardyChief Executive Officer↗
- Mar 16, 26Compensationamount n/aBrian MuellerEVP, Chief Financial Officer↗
- Mar 16, 26Tax$420KGeorge Eric DavisEVP, Chief Legal Officer↗
- Mar 16, 26Compensationamount n/aGeorge Eric DavisEVP, Chief Legal Officer↗
- Mar 16, 26Compensationamount n/aCharles Greg GuyerEVP, Chief Technical Officer↗
- Mar 16, 26Compensationamount n/aGregory R FribergEVP, Chief R&D Officer↗
- Mar 16, 26Compensationamount n/aCristin HubbardEVP, Chief Commercial Officer↗
- Mar 13, 26Tax$172KAlexander HardyChief Executive Officer↗
- Mar 13, 26Tax$582KBrian MuellerEVP, Chief Financial Officer↗
- Mar 13, 26Tax$533KCharles Greg GuyerEVP, Chief Technical Officer↗
- Feb 25, 26Compensationamount n/aBrian MuellerEVP, Chief Financial Officer↗
- Feb 25, 26Compensationamount n/aBrian MuellerEVP, Chief Financial Officer↗
- Feb 25, 26Compensationamount n/aBrian MuellerEVP, Chief Financial Officer↗
- Feb 25, 26Compensationamount n/aGeorge Eric DavisEVP, Chief Legal Officer↗
- Feb 25, 26Compensationamount n/aGeorge Eric DavisEVP, Chief Legal Officer↗
- Feb 25, 26Compensationamount n/aGeorge Eric DavisEVP, Chief Legal Officer↗
- Feb 25, 26Compensationamount n/aCharles Greg GuyerEVP, Chief Technical Officer↗
The full record holds 319 transactions and goes back to Apr 29, 22.
Its sector and its market
Biomarin Pharmaceutical Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Biomarin Pharmaceutical Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Biomarin Pharmaceutical Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 2,506 documents on file, from Jul 29, 1999 to Oct 6, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.